Publication

[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S. & van Oordt, C. W. M. D. H., 9-Nov-2019, In : European Journal of Nuclear Medicine and Molecular Imaging. 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., ... van Oordt, C. W. M. D. H. (2019). [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-019-04555-6

Author

van Helden, E. J. ; Elias, S. G. ; Gerritse, S. L. ; van Es, S. C. ; Boon, E. ; Huisman, M. C. ; van Grieken, N. C. T. ; Dekker, H. ; van Dongen, G. A. M. S. ; Vugts, D. J. ; Boellaard, R. ; van Herpen, C. M. L. ; de Vries, E. G. E. ; Oyen, W. J. G. ; Brouwers, A. H. ; Verheul, H. M. W. ; Hoekstra, O. S. ; van Oordt, C. W. Menke-van der Houven. / [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. In: European Journal of Nuclear Medicine and Molecular Imaging. 2019.

Harvard

van Helden, EJ, Elias, SG, Gerritse, SL, van Es, SC, Boon, E, Huisman, MC, van Grieken, NCT, Dekker, H, van Dongen, GAMS, Vugts, DJ, Boellaard, R, van Herpen, CML, de Vries, EGE, Oyen, WJG, Brouwers, AH, Verheul, HMW, Hoekstra, OS & van Oordt, CWMDH 2019, '[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer', European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-019-04555-6

Standard

[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. / van Helden, E. J.; Elias, S. G.; Gerritse, S. L.; van Es, S. C.; Boon, E.; Huisman, M. C.; van Grieken, N. C. T.; Dekker, H.; van Dongen, G. A. M. S.; Vugts, D. J.; Boellaard, R.; van Herpen, C. M. L.; de Vries, E. G. E.; Oyen, W. J. G.; Brouwers, A. H.; Verheul, H. M. W.; Hoekstra, O. S.; van Oordt, C. W. Menke-van der Houven.

In: European Journal of Nuclear Medicine and Molecular Imaging, 09.11.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC et al. [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2019 Nov 9. https://doi.org/10.1007/s00259-019-04555-6


BibTeX

@article{22be926cb15c4a15962e99fa9cc8afa1,
title = "[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer",
abstract = "Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [Zr-89]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. Patients and methods PET/CT imaging of [Zr-89]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m(2)",
keywords = "Colorectal cancer, Targeted therapy, Cetuximab, Imaging biomarker, PET, CT, GROWTH-FACTOR RECEPTOR, EGFR EXPRESSION, PHASE-I, TUMOR, PHARMACOKINETICS, METAANALYSIS, PROGNOSIS, SURVIVAL, BENEFIT",
author = "{van Helden}, {E. J.} and Elias, {S. G.} and Gerritse, {S. L.} and {van Es}, {S. C.} and E. Boon and Huisman, {M. C.} and {van Grieken}, {N. C. T.} and H. Dekker and {van Dongen}, {G. A. M. S.} and Vugts, {D. J.} and R. Boellaard and {van Herpen}, {C. M. L.} and {de Vries}, {E. G. E.} and Oyen, {W. J. G.} and Brouwers, {A. H.} and Verheul, {H. M. W.} and Hoekstra, {O. S.} and {van Oordt}, {C. W. Menke-van der Houven}",
year = "2019",
month = "11",
day = "9",
doi = "10.1007/s00259-019-04555-6",
language = "English",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "SPRINGER",

}

RIS

TY - JOUR

T1 - [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

AU - van Helden, E. J.

AU - Elias, S. G.

AU - Gerritse, S. L.

AU - van Es, S. C.

AU - Boon, E.

AU - Huisman, M. C.

AU - van Grieken, N. C. T.

AU - Dekker, H.

AU - van Dongen, G. A. M. S.

AU - Vugts, D. J.

AU - Boellaard, R.

AU - van Herpen, C. M. L.

AU - de Vries, E. G. E.

AU - Oyen, W. J. G.

AU - Brouwers, A. H.

AU - Verheul, H. M. W.

AU - Hoekstra, O. S.

AU - van Oordt, C. W. Menke-van der Houven

PY - 2019/11/9

Y1 - 2019/11/9

N2 - Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [Zr-89]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. Patients and methods PET/CT imaging of [Zr-89]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m(2)

AB - Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [Zr-89]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. Patients and methods PET/CT imaging of [Zr-89]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m(2)

KW - Colorectal cancer

KW - Targeted therapy

KW - Cetuximab

KW - Imaging biomarker

KW - PET

KW - CT

KW - GROWTH-FACTOR RECEPTOR

KW - EGFR EXPRESSION

KW - PHASE-I

KW - TUMOR

KW - PHARMACOKINETICS

KW - METAANALYSIS

KW - PROGNOSIS

KW - SURVIVAL

KW - BENEFIT

U2 - 10.1007/s00259-019-04555-6

DO - 10.1007/s00259-019-04555-6

M3 - Article

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -

ID: 107589950